Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 669

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Open access
Kim, Youn H, Bagot, Martine, Pinter-Brown, Lauren, Rook, Alain H, Porcu, Pierluigi, Horwitz, Steven M, Whittaker, Sean, Tokura, Yoshiki, Vermeer, Maarten, Zinzani, Pier Luigi, Sokol, Lubomir, Morris, Stephen, Kim, Ellen J, Ortiz-Romero, Pablo L, Eradat, Herbert, Scarisbrick, Julia, Tsianakas, Athanasios, Elmets, Craig, Dalle, Stephane, Fisher, David C, Halwani, Ahmad, Poligone, Brian, Greer, John, Fierro, Maria Teresa, Khot, Amit, Moskowitz, Alison J, Musiek, Amy, Shustov, Andrei, Pro, Barbara, Geskin, Larisa J, Dwyer, Karen, Moriya, Junji, Leoni, Mollie, Humphrey, Jeffrey S, Hudgens, Stacie, Grebennik, Dmitri O, Tobinai, Kensei, Duvic, Madeleine, Abhyankar, Sunil, Akilov, Oleg, Alpdogan, Onder, Beylot-Barry, Marie, Boh, Erin, Caballero, Dolores, Cowan, Richard, Dreno, Brigitte, Dummer, Reinhard, Fenske, Timothy, Foss, Francine, Fukuhara, Noriko, Giri, Pratyush, Habe, Koji, Hamada, Toshihisa, Hatake, Kiyohiko, Iida, Shinsuke, Ishikawa, Osamu, Iversen, Lars, Kiyohara, Eiji, Koga, Hiroshi, Korman, Neil, Kuss, Bryone Jean, Lamar, Zanetta, Lansigan, Frederick, Lechowicz, Mary Jo, Lerner, Adam, Magnolo, Nina, Mark, Lawrence, Miyagaki, Tomomitsu, Munoz, Javier, Nicolay, Jan Peter, Nishiwaki, Kaoru, Okamoto, Hiroyuki, Ohtsuka, Mikio, Pacheco, Theresa, Querfeld, Christiane, Rapini, Ronald Peter, Sano, Shigetoshi, Tanaka, Maiko, Tharp, Michael D., Uehara, Jiro, Wada, Hidefumi, Wells, Jillian, Wilcox, Ryan A., William, Basem, Yonekura, Kentaro · 2018 · The Lancet Oncology

Abstract

BACKGROUND Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor 4, with vorinostat in patients with previously treated cutaneous T-cell lymphoma. METHODS In this open-label, international, phase 3, randomised controlled trial, we recruited patients with relapsed or refractory mycosis fungoides or Sézary syndrome at 61 medical centres in the USA, Denmark, France, Italy, Germany, the Netherlands, Spain, Switzerland, the UK, Japan, and Australia. Eligible patients were aged at least 18 years (in Japan, ≥20 years), had failed (for progression or toxicity as assessed by the principal investigator) at least one previous systemic therapy, and had an Eastern Cooperative Oncology Group performance score of 1 or less and adequate haematological, hepatic, and renal function. Patients were randomly assigned (1:1) using an interactive voice web response system to mogamulizumab (1·0 mg/kg intravenously on a weekly basis for the first 28-day cycle, then on days 1 and 15 of subsequent cycles) or vorinostat (400 mg daily). Stratification was by cutaneous T-cell lymphoma subtype (mycosis fungoides vs Sézary syndrome) and disease stage (IB-II vs III-IV). Since this study was open label, patients and investigators were not masked to treatment assignment. The primary endpoint was progression-free survival by investigator assessment in the intention-to-treat population. Patients who received one or more doses of study drug were included in the safety analyses. This study is ongoing, and enrolment is complete. This trial was registered with ClinicalTrials.gov, number NCT01728805. FINDINGS Between Dec 12, 2012, and Jan 29, 2016, 372 eligible patients were randomly assigned to receive mogamulizumab (n=186) or vorinostat (n=186), comprising the intention-to-treat population. Two patients randomly assigned to mogamulizumab withdrew consent before receiving study treatment; thus, 370 patients were included in the safety population. Mogamulizumab therapy resulted in superior investigator-assessed progression-free survival compared with vorinostat therapy (median 7·7 months [95% CI 5·7-10·3] in the mogamulizumab group vs 3·1 months [2·9-4·1] in the vorinostat group; hazard ratio 0·53, 95% CI 0·41-0·69; stratified log-rank p<0·0001). Grade 3-4 adverse events of any cause were reported in 75 (41%) of 184 patients in the mogamulizumab group and 76 (41%) of 186 patients in the vorinostat group. The most common serious adverse events of any cause were pyrexia in eight (4%) patients and cellulitis in five (3%) patients in the mogamulizumab group; and cellulitis in six (3%) patients, pulmonary embolism in six (3%) patients, and sepsis in five (3%) patients in the vorinostat group. Two (67%) of three on-treatment deaths with mogamulizumab (due to sepsis and polymyositis) and three (33%) of nine on-treatment deaths with vorinostat (two due to pulmonary embolism and one due to bronchopneumonia) were considered treatment-related. INTERPRETATION Mogamulizumab significantly prolonged progression-free survival compared with vorinostat, and could provide a new, effective treatment for patients with mycosis fungoides and, importantly, for Sézary syndrome, a subtype that represents a major therapeutic challenge in cutaneous T-cell lymphoma. FUNDING Kyowa Kirin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30379-6

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 1

  1. Korgavkar, 2013, Changing incidence trends of cutaneous T-cell lymphoma, JAMA Dermatol, 149, 1295, 10.1001/jamadermatol.2013.5526 · doi:10.1001/jamadermatol.2013.5526

Cited by

See all 669

Metadata

Authors
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P. L., Sokol, L., Morris, S., Kim, E. J., Ortiz-Romero, P. L., Eradat, H., Scarisbrick, J., Tsianakas, A., Elmets, C., Dalle, S., Fisher, D. C., Halwani, A., Poligone, B., Greer, J., Fierro, M. T., Khot, A., Moskowitz, A. J., Musiek, A., Shustov, A., Pro, B., Geskin, L. J., Dwyer, K., Moriya, J., Leoni, M., Humphrey, J. S., Hudgens, S., Grebennik, D. O., Tobinai, K., Duvic, M., Abhyankar, S., Akilov, O., Alpdogan, O., Beylot-Barry, M., Boh, E., Caballero, D., Cowan, R., Dreno, B., Dummer, R., Fenske, T., Foss, F., Fukuhara, N., Giri, P., Habe, K., Hamada, T., Hatake, K., Iida, S., Ishikawa, O., Iversen, L., Kiyohara, E., Koga, H., Korman, N., Kuss, B. J., Lamar, Z., Lansigan, F., Lechowicz, M. J., Lerner, A., Magnolo, N., Mark, L., Miyagaki, T., Munoz, J., Nicolay, J. P., Nishiwaki, K., Okamoto, H., Ohtsuka, M., Pacheco, T., Querfeld, C., Rapini, R. P., Sano, S., Tanaka, M., Tharp, M. D., Uehara, J., Wada, H., Wells, J., Wilcox, R. A., William, B., & Yonekura, K.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2018-09
Volume
19
Issue
9
Pages
1192-1204
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2885239461
Cited by
669
References
28
FWCI
57.28
Type
journal article
Language
en
Update notices
erratum (2018-11-01)
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Eisai
  • Merck
  • Kyowa Hakko Kirin
  • Spectrum Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30379-6
The paper
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P. L., Sokol, L., Morris, S., Kim, E. J., Ortiz-Romero, P. L., Eradat, H., Scarisbrick, J., Tsianakas, A., Elmets, C., Dalle, S., . . . Yonekura, K. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30379-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.